Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.54 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11289375 | 0.83 | SMN1; SMN2 (0.58) | MAPK1MAPTSMN1; SMN2GAAALDH3A1 | |
| SCHEMBL1857426 | 0.82 | LMNA (0.49) | MAPK1MAPTSMN1; SMN2ALDH1A1AR | |
| SCHEMBL1239096 | 0.82 | SLC6A9 (0.58) | MAPK1SMN1; SMN2ALDH1A1ARKDM4E | |
| SCHEMBL1859720 | 0.82 | MAPT (0.52) | MAPK1MAPTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL9424288 | 0.82 | ALDH1A1 (0.55) | MAPK1MAPTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL232730 | 0.81 | ALDH1A1 (0.55) | MAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL31575883 | 0.81 | ALDH1A1 (0.55) | MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL709382 | 0.80 | ALDH1A1 (0.54) | MAPTSMN1; SMN2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL31399315 | 0.80 | DRD2 (0.49) | MAPK1ALDH1A1ARKDM4EHPGD | |
| SCHEMBL20181102 | 0.80 | DRD2 (0.49) | MAPK1ALDH1A1ARKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAPK1 1216/4885MAPT 3072/4885SMN1; SMN2 3099/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAPK1 1216/4885MAPT 3072/4885SMN1; SMN2 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.